Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
复制标题
DOI：
10.1155/2015/712438
复制
发表时间：
2015
影响因子：
--
通讯作者：
Sandaltzopoulos R
中科院分区：
文献类型：
--
作者：
Karapetsas A;Giannakakis A;Dangaj D;Lanitis E;Kynigopoulos S;Lambropoulou M;Tanyi JL;Galanis A;Kakolyris S;Trypsianis G;Coukos G;Sandaltzopoulos R
卵巢癌细胞毒性T淋巴细胞浸润是一个有利的预后因素。采用差异表达的方法，我们最近确定了一些基因与CD 8 + T细胞浸润的早期卵巢肿瘤。在本研究中，我们通过qPCR验证了编码跨膜蛋白GPC 6和TMEM 132 D的两种基因在早期卵巢癌患者队列中的表达。两种基因的表达与CD 8A的mRNA水平呈正相关，CD 8A是T淋巴细胞浸润的标志物[Pearson系数分别为：0.427（p = 0.0067）和0.861（p < 0.0001）]。GPC 6和TMEM 132 D的表达也记录在各种卵巢癌细胞系中。重要的是，Kaplan-Meier生存分析显示，GPC 6和/或TMEM 132 D的高mRNA水平与早期卵巢癌患者总体生存率的增加显著相关（p = 0.032）。因此，GPC 6和TMEM 132 D可以作为CD 8 + T淋巴细胞浸润的预测因子，并作为早期卵巢癌的有利预后标志物，对诊断、预后和肿瘤免疫印迹具有重要意义。
Infiltration of cytotoxic T-lymphocytes in ovarian cancer is a favorable prognostic factor. Employing a differential expression approach, we have recently identified a number of genes associated with CD8+ T-cell infiltration in early stage ovarian tumors. In the present study, we validated by qPCR the expression of two genes encoding the transmembrane proteins GPC6 and TMEM132D in a cohort of early stage ovarian cancer patients. The expression of both genes correlated positively with the mRNA levels of CD8A, a marker of T-lymphocyte infiltration [Pearson coefficient: 0.427 (p = 0.0067) and 0.861 (p < 0.0001), resp.]. GPC6 and TMEM132D expression was also documented in a variety of ovarian cancer cell lines. Importantly, Kaplan-Meier survival analysis revealed that high mRNA levels of GPC6 and/or TMEM132D correlated significantly with increased overall survival of early stage ovarian cancer patients (p = 0.032). Thus, GPC6 and TMEM132D may serve as predictors of CD8+ T-lymphocyte infiltration and as favorable prognostic markers in early stage ovarian cancer with important consequences for diagnosis, prognosis, and tumor immunobattling.